CCHT(SZ:000661) news flash·2025-04-20 07:52Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application of a new specification of recombinant human follicle-stimulating hormone injection, specifically the 66μg (900IU) dosage [1] Group 1 - The new specification is intended to meet the same indications as the previously approved specifications, enhancing individualized treatment options for different patients [1] - This approval is seen as a supplement to the already approved specifications, which will further satisfy market demand and improve the company's market competitiveness [1] - However, the sales of the product are subject to various influencing factors, leading to inherent uncertainties [1]